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Abstract 
BACKGROUND: The expression of a gene is a process that conveys information of genes to synthesise gene 
product is functional. Alterations of the molecular biology in breast cancer are very complex because of many 
factors play a role in the tumorigenesis. RhoC is a prometastases gene. The PI3K gene is crucial in the regulation 
of multiple cellular functions, including cell growth, proliferation, metabolism and angiogenesis. 
AIM: This study aims to compare of RhoC and PI3K gene expression on the breast cancer tissue and benign 
tumour tissue. 
MATERIAL AND METHODS: Expression of the RhoC and PI3K genes was carried out with qPCR. The absolute 
quantification method was using breast cancer tissue. As a comparison, benign tumours (FATs) tissue was 
carried out. The standard curves were obtained from cloning target genes, which were inserted into the gGEMT-
easy vector from E. coli. The gene expression data was carried out by t-test to see the mean difference between 
the expression of breast cancer tissue and benign tumours (FATs) with a value of p ≤ 0.005 in RhoC and PI3K 
gene expression. And the relationship between expressions was done by Pearson correlation test. 
RESULTS: The results showed that it was found that PI3K gene expression on breast cancer tissue was higher 
than the number in a benign tumour (fibroadenoma mammae) as an endogenous control. And also, the 
expression of RhoC is much lower on breast cancer tissue compared with a benign tumour.  
CONCLUSION: This study concluded that expression of RhoC affects the expression of PI3K so that the thing 
this is what causes the proliferation and began to provide support aggressive cancer cells in the breast. 
 
 
 
 
 
 
Introduction 
 
Fibroadenoma, or fibroadenoma mammae 
(FAM), is one of the most common types of benign 
tumours that occur in the breast. Fibroadenoma is 
round with a firm boundary and has a chewy 
consistency with a smooth surface [1]. The majority of 
breast disorders are benign lesions; malignant lesions 
are only 20% of all abnormalities in the breast. The 
incidence of this benign disorder begins at the age of 
the second decade, and the peak is in the fourth and 
fifth decades of life. A small portion of benign tumours 
is associated with breast cancer [2].  
Cancer is a non-communicable disease 
characterised by abnormal/continuous and 
uncontrolled cell growth that can damage the 
surrounding tissue and can spread to places far from 
its origin called metastasis. Cancer cells can originate 
or grow from any cell in the human body. Cancer has 
become a health problem in the world, including 
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Indonesia. The type of cancer that many women 
suffer and fear is breast cancer [3]. 
Histopathologically most mammary lesions 
consist of one or more lumps whose shapes and sizes 
vary greatly. These lumps can be firmly bound or not, 
single or multiple nodules, soft or hard, can be moved 
from the bottom or not. This can help distinguish 
benign lesions or malignant lesions in the breast [4], 
[1]. However, in molecular biology, there is still a little-
known difference in genetic profile between 
fibroadenoma mammae and Ca mammae (breast 
cancer). The profile of gene expression in breast 
cancer has been studied intensively. Gene expression 
profiling is enabling scientists to understand the 
heterogeneous nature of breast cancer on a genomic 
level. 
Breast cancer is currently a problem in the 
health sector because the incidence of breast 
carcinoma increases from year to year in both 
developed countries and developing countries like 
Indonesia. The breast cancer mortality rate also 
increased sharply [5]. Based on the Globocan 
estimate, the 2012 International Agency for Research 
on Cancer (IARC), breast cancer is cancer with the 
highest percentage of new cases (43.3%) and the 
highest percentage of deaths (12.9%) in women in the 
world. Based on data from the Indonesian Ministry of 
Health (2010), the prevalence of breast cancer in 
Indonesia reached 0.5 per 1000 women [6]. 
RhoC is known to be a pro-metastasis gene 
belonging to the RAS superfamily. RhoC expression 
increases in gastric cancer, and it will activate the 
PI3K / Akt pathway to induce the cell invasion. This 
mechanism is different in some cancers [7]. RhoC is 
also an effector on the MAPK pathway that increases 
VEGF, fibroblast growth factors, and regulates the 
expression of IL-6 and IL-8 [8], [9]. Changes in the 
expression of RhoC are associated with increased cell 
proliferation and cause tumours to become malignant 
[10]. RhoC is a negative mediator from affects the 
PI3K/Akt and MAPK pathways [11]. 
PI3Ks are a family of intracellular enzymes 
that are associated with signal transduction, are 
involved in cellular functions such as cell growth, 
proliferation, differentiation, motility, survival and 
intracellular traffic and are in turn involved in cancer 
[12]. The PI3K/Akt pathway is activated by changes in 
the expression of RhoC protein [13]. On the PI3K line, 
activating Akt is called the PI3K/Akt line. This pathway 
contains many activators, inhibitors, effectors and 
second messengers. Several studies have shown that 
high activity of PI3K/Akt signals will induce resistance 
of chemotherapy and HER-2 therapy targets. 
Activation in the PI3K/Akt pathway will promote cell 
proliferation [14]. 
Activation of PI3K/Akt causes interference 
with cell growth control. If there is a change in 
expression, it will cause metastasis, angiogenesis and 
therapeutic resistance and reduce PTEN activity [15]. 
Thus, the molecular mechanism that passes through 
the complex pathway into the future is considered to 
be one of the most attractive targets for the 
development of anticancer agents [16]. 
Also, PI3K pathways are stimulated as a 
result of many growth physiological factors and 
regulators. Whatever the mechanism, PI3K activation 
will cause a disruption of control of normal cell growth 
and cell continuity, which contributes to competitive 
growth, metastatic ability, frequent resistance to 
therapy. This pathway is an attractive target for the 
development of new anti-cancer [13]. The expression 
profile has the potential to differentiate between 
Fibroadenoma and breast cancer. So, this can be 
used as a guide for the diagnosis and future 
prognosis. Therefore, the RhoC inhibition target is 
possible as an alternative path in activating PI3K. So 
PI3K has the potential to target the care of breast 
cancer people [17], [18]. Changes in the level of 
mRNA, which will be related to expression can be 
used as biomarkers to detect disease early and can 
be intervened at the stage of disease progression. 
 
 
Material and Methods 
 
Sample 
The sample is fresh tissue of breast cancer 
and benign tumour tissue stored in the BioBank 
Biomedical Laboratory Tissue. Samples from breast 
cancer and benign tumour tissue consisted of 30 
breast cancer tissues and 30 benign tumour tissues. 
For breast cancer tissue taken from 30-50 years old. 
This group was taken because it is the largest 
population of breast cancer whose tissue is stored in 
the BioBank Tissue of Faculty of Medicine, Andalas 
University.  
 
Total RNA isolation 
Total RNA from breast cancer tissue and 
benign tumours (FAM) was isolated using Pure Link 
Ambion RNA isolation kit (12183018A). The initial 
stage of sample preparation is homogenised by using 
the stator-rotor technique to make homogeneous from 
the tissue. After the isolation process is complete, 
save the total RNA at -80°C. 
 
cDNA synthesis 
The synthesis composition of the total cDNA 
was 5 µg total RNA, 1 x RT buffer, 20 pmol oligodT, 4 
mM dNTP, 10 mM DTT, 40 U SuperScript TMII RTase 
and H2O-DEPC enzymes with a reaction volume of 20 
μl. Total cDNA synthesis was carried out at 52°C for 
50 minutes with the work protocol by the manual kit 
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(Isd cDNA synthesis, Biorad). Check the success of 
cDNA synthesis using NanoDrop. 
Table 1: Primer design 
 
 
Amplification of the real-time PCR of the 
 target gene 
Each gene was amplified with an SYBR 
Green amplification kit. The PCR program as follows: 
Predenaturation of 95.0°C for 3 minutes. Denaturation 
of 95.0°C for 5 seconds, annealing gradient of 50-
60°C for 5 seconds, for 39 cycles. Add a melting curve 
of 65.0°C to 95.0°C with an increase of 0.5°C for 5 
seconds. The miRNA is amplified wherein it contains 
the primary HSA-miR-16-5p LNA PCR set, HSA-MIR-
10b-5p LNA ™ PCR primer set and HSA-miR-21-5p 
primary PCR LNA set (Exiqon, Denmark), ExiLENT 
SYBR Green master (Exiqon, Denmark). The PCR 
program as follows Predenaturation 95.0°C for 10 
minutes, Denaturation 95.0°C for 10 seconds, 
gradient annealing 55 – 65°C for 1 minute, for 39 
cycles. Add a melting curve of 60.0°C to 95.0°C with 
an increase of 0.5°C for 5 seconds. 
 
Data analysis 
The expression of PI3K and RhoC genes is 
done by absolute quantification examination. Making 
standard curves from target genes is based on the 
Whelan et al., 2003 method [19]. Differences in mean 
expression of PI3K and RhoC between breast cancer 
tissue and benign tumours were carried out by t-test 
with 95% significance level at p ≤ 0.05. Furthermore, 
the relationship between RhoC and PI3K gene 
expression was carried out by the Pearson correlation 
test with a correlation value of 0-1. 
 
 
Results 
 
qPCR RhoC gene 
Plasmids with the insertion of the RhoC gene 
for standard curves and target genes together, so that 
the standard curve is obtained, as shown in Figure 1 
below. From the results of run qPCR, the melting 
curve is obtained, as shown in Figure 1b. 
 
Figure 1: Standard Curve graph of PI3K gene insertion in vector 
and graph melting peak RhoC gene from Real-time PCR 
 
The results of the expression of the RhoC 
gene from absolute quantification Real-time PCR 
were obtained in the form of a copy number, and from 
this study, it was found that the expression of the 
RhoC gene in breast cancer tissue was lower than the 
RhoC gene expression in benign tumour tissue 
(Figure 2).  
Table 2: RhoC gene expression between breast cancer tissue 
and fibroadenoma tissue 
Group Expression SD p 
Breast Cancer Tissue 3.701 0.756 0.005 
Fibroadenoma Tissue 4.463 0.939 
 
From this study, there was a significant 
difference in RhoC gene expression between breast 
cancer tissue and benign tumour tissue with a value of 
p < 0.05 (p = 0.0001) 
 
Figure 2: Boxplot graph of RhoC gene expression in breast cancer 
tissue and fibroadenoma tissue (benign tumour) 
 
qPCR PI3K gene 
Plasmids with PI3K gene insertion for 
standard curves and target genes are concurrent so 
that the standard curve is obtained, as shown in figure 
3a below. From the results of running qPCR, the 
melting curve is obtained, as shown in Figure 3b. 
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Figure 3. Standard Curve graph of PI3K gene insertion on vector 
and graph melting peak PI3K gene from Real-time PCR 
 
The results of the expression of the PI3K 
gene from absolute quantification of real-time PCR 
were obtained in the form of copy number values.  
Table 3: PI3K gene expression between breast cancer tissue 
and fibroadenoma tissue 
Group Expression SD p 
Breast Cancer Tissue 4.171 0.569 0.001 
Fibroadenoma Tissue 3.620 0.667 
 
From this study, it was found that the 
expression of the PI3K gene in breast cancer tissue 
was higher than the PI3K gene expression in benign 
tumour tissue. 
 
Figure 4: Boxplot graph of PI3K gene expression in breast cancer 
tissue and fibroadenoma tissue (benign tumour) 
 
 
 
Discussion 
 
Molecular changes in the growth of breast 
cancer are very complex. At first, this change was 
based on changes in three groups of genes that 
control cancer growth. The main hereditary gene that 
influences the growth of breast cancer known today is 
BRCA1 / 2, which is a suppressor tumour gene. It 
turns out that this gene only contributes 15% [20]. 
The expression of the RhoC gene in breast 
cancer tissue is lower than fibroadenoma tissue 
(FAMs). The difference in expression of this RhoC 
gene between breast cancer tissue and fibroadenoma 
was significant at p = 0.0001 (p < 0.005). It is 
suspected that the breast cancer tissue in this sample 
is still in the early stages of breast cancer and has not 
experienced metastasis. Lower expression of the 
RhoC gene in breast cancer tissue than FAMs is likely 
because breast cancer tissue is a network of primary 
breast cancer/primary tumour. 
Lower expression of the RhoC gene in breast 
cancer tissue than FAMs is likely because breast 
cancer tissue is a network of primary breast 
cancer/primary tumour. But on the other hand, in other 
studies on breast cancer tissue that had metastasised 
an increased expression of RhoC when compared to 
normal tissue. But it is not stated whether the normal 
network is the source. Because it can be assumed 
that it is different between normal networks and FAMs 
tissue, these results can explain the underlying 
mechanism and provide new therapeutic targets for 
inhibiting invasion and metastasis from cancer cells 
[21]. 
Conversely, if the expression of RhoC is 
excessive, this causes degradation and reconstruction 
of the Extracellular Matrix (ECM), which helps cells 
escape from their tissues. So that it will increase cell 
motility and increase the ability to be invasive [22]. 
Uniquely from this protein RhoC, gene damage 
(mutation) is not found in RhoC. Changes in the 
expression are not only caused by mutations, but 
there are other factors involved, such as the effect of 
epigenetic miRNA and chromosome modification and 
can also be caused by disturbances at the post-
transcription and post-translational stages. 
RhoC functions as a button in the signal 
transduction of the cascades. RhoC promotes the 
reorganisation of the cytoskeleton, regulates cell 
shape and cell motility. RhoC can activate formins 
such as MDIA1 and FMNL2 to change the shape of 
the cell cytoskeleton [23], [24]. And also, RhoC affects 
the PI3K pathway, which is a biomarker of 
proliferation and initiation of invasion [25]. As is known 
in human's phosphatidylinositol 3-kinase/AKT is a 
target of the rapamycin (PI3K / Akt / mTOR) pathway 
which plays an important role in the intracellular 
signalling system that guides cell growth and cell 
defence. It is estimated that 70-75% of breast cancers 
express the ER-associated with this pathway. Many 
patients with ER + will be more resistant to 
chemotherapy. Knowing the state of PI3K expression 
will help in the prognosis for how long to use 
endocrine hormone therapy and provide an overview 
of the use or delay of using chemotherapy [26]. 
In this study, it was found that the expression 
of PI3K in breast cancer tissue was higher than that of 
Fibroadenoma. James Ryan and colleagues also 
found that PI3K expression in breast cancer tissue 
was higher than in Fibroadenoma [27]. 
Activation of PI3K activates Akt, so it is known 
Group
Fibro Adenomas TissueBreast Cancer Tissue
P
I3
K
 G
e
n
e
 E
x
p
re
s
s
io
n
5.50
5.00
4.50
4.00
3.50
3.00
2.50
Arisanty et al. The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumor Tissue 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         5 
 
as PI3K/Akt, which disrupts cell growth control. This is 
what happens in breast cancer tissue has higher 
expression of PI3K compared to FAMs tissue. So that 
if there is a change in expression, it will potentially 
cause metastasis, angiogenesis and therapeutic 
resistance. Besides that, the increase in expression of 
PI3K will reduce PTEN activity [15]. The PI3K/Akt 
pathway is activated by changes in the expression of 
RhoC protein. The high intracellular activity on the 
phosphatidylinositol-3 kinase (PI3K) pathway is 
common in breast cancer [13]. Thus, the molecular 
mechanism that passes through the complex pathway 
into the future is considered one of the most attractive 
targets for the development of anticancer agents [16]. 
Activation in the PI3K/Akt pathway will promote cell 
proliferation [14]. Although the expression of PI3K is 
higher in breast cancer tissue, when expression of 
RhoC is still low in breast cancer tissue can be used 
as a signal that the cancer cell has not yet invaded, 
because it has not affected the extracellular matrix to 
change, where changes in the extracellular matrix 
indicate that the cell cancer will experience invasion 
and metastasis. 
Also, PI3K pathways are stimulated as a 
result of many growth physiological factors and 
regulators. Whatever the mechanism, activation of 
PI3K will cause disruption of control of cell growth and 
cell continuity, which contributes to competitive growth 
and metastatic ability. So that resistance often occurs 
in therapy. This pathway is an attractive target for the 
development of new cancellers [13]. Therefore, the 
target of inhibiting PI3K has the potential to target the 
care of breast cancer people [17], [18]. And it will be 
even more interesting, the potential for inhibition of 
genes that are upstream, namely RhoC, will inhibit the 
process of cancer cells becoming more malignant and 
undergoing invasion and metastasis. So that RhoC 
can be used as a good marker to determine breast 
cancer that is very aggressive and motile and can 
provide guidance in therapy for intervention before 
developing into metastasis so that it can identify 
primary breast cancer cells with breast cancer that 
have the potential to metastasise [28]. Of research is 
it can be concluded that an expression of RhoC affect 
the expression of PI3K so that the thing this is what 
causes the proliferation and began to provide support 
aggressive cancer cells in the breast. 
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